3 Under-Loved Dividend Darlings for Your Portfolio

Drugmakers are a staple in dividend investors portfolios, but Bristol-Myers (BMY), Johnson & Johnson (JNJ), and Merck (MRK) may be among the best for investors to buy and hold.

Todd Campbell
Todd Campbell
Apr 4, 2014 at 9:30AM
Health Care

Bristol-Myers (NYSE:BMY)Johnson & Johnson (NYSE:JNJ), and Merck (NYSE:MRK), are among the most widely owned dividend paying drug companies and sales at all three are feeling the patent pinch.

With the patent cliff ready to erase $66 billion in industry sales next year and shares trading at lofty levels, should these three be in your dividend portfolio?

In the following slideshow, you'll find info on which patent losses are taking their toll, which products are driving sales higher, and whether dividend payouts could grow or shrink.